1.
J Pediatr
; 155(2): 289-91, 2009 Aug.
Article
in English
| MEDLINE
| ID: mdl-19619754
ABSTRACT
We report the use of anti-interleukin-5 (mepolizumab) during an 18-month period in a pediatric hypereosinophilic syndrome. Infusions every 3 months allowed better control of hypereosinophilic syndrome flares and maintained blood eosinopenia with significantly less steroid use compared with all other therapies (prednisolone alone, interferon alpha, or imatinib mesylate).